Aptamer‐SH2 superbinder‐based targeted therapy for pancreatic ductal adenocarcinoma

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) exhibits the poorest prognosis of all solid tumors with a 5‐year survival rate of less than 10% and a median survival of 6 months after diagnosis. Numerous targeted agents have been developed and evaluated to improve the survival benefit in patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, An‐Dong, Zhou, Jie, Bi, Xiao‐Yang, Hou, Guo‐Qing, Li, Shawn Shun‐Cheng, Chen, Qing, Xu, Hui, Cao, Xuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7908048/
https://www.ncbi.nlm.nih.gov/pubmed/33783993
http://dx.doi.org/10.1002/ctm2.337

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7908048/
https://www.ncbi.nlm.nih.gov/pubmed/33783993
http://dx.doi.org/10.1002/ctm2.337

Ejemplares similares